Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity

Objectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity. Background: Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Current s...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, Tammy Cosman, PhD, Muhammad M. Alhussein, MD, Nidhi Kumar Tyagi, MBChB, Sarah Karampatos, MS, Carly C. Barron, MD, MS, Douglas Wright, MD, Vikas Tandon, MD, Patrick Magloire, MD, Philip Joseph, MD, David Conen, MD, MPH, P.J. Devereaux, MD, PhD, Peter M. Ellis, MBBS, MMed, PhD, Som D. Mukherjee, MD, MS, Sukhbinder Dhesy-Thind, MD, MS
Formaat: Artikel
Taal:English
Gepubliceerd in: Elsevier 2019-09-01
Reeks:JACC. CardioOncology
Onderwerpen:
breast cancer
cardiomyopathy
HER2
trastuzumab
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666087319300055

Internet

http://www.sciencedirect.com/science/article/pii/S2666087319300055

Gelijkaardige items